Hormonal/Women

DIM

Cruciferous vegetable compound that shifts estrogen metabolism and may support cervical and prostate cell health in hormone-sensitive adults.

DIM

DIM

50
score
C
evidence
Caution
risk

Proven Benefits

01Modulates estrogen metabolism
02May support cervical health
03May lower PSA in men
04May reduce thyroid nodules
05May improve hormonal acne

Chemical Forms

Recommended
  • DIM-phosphatidylcholine complex (e.g., BioResponse DIM)
  • Standardized DIM capsules
Avoid
  • Indole-3-carbinol (I3C) — less stable and less predictable metabolism
  • Unstandardized cruciferous extracts with unknown DIM yield
Expert Note

Free DIM is poorly absorbed. Complexing DIM with phosphatidylcholine markedly improves bioavailability over plain powder. Standardized capsules ensure a known quantity of active compound, whereas I3C is a precursor with variable conversion and potential for other metabolites.

Protocol

Amount
100-300 mg
Frequency
Once daily
When
With a meal containing fat to improve absorption.

Condition-Based Dosing

General estrogen metabolism support
100-200 mg daily
Cervical dysplasia or hormone-sensitive tissue support (medical supervision)
200-300 mg daily
Body weight >90 kg
Up to 300 mg daily

Safety & Limits

Upper Safe Limit
No official UL established; doses above 600 mg/day have not been well studied long-term and may cause headaches or GI distress.
Cycling
Safe for continuous use

Contraindications

Pregnancy or breastfeeding — insufficient safety data
Hormone-sensitive cancers (breast, ovarian, uterine) — use only under oncologist supervision
Hypothyroidism or Hashimoto's without monitoring — may alter thyroid hormone requirements
Oral contraceptives — may theoretically reduce efficacy

Synergies

Calcium D-Glucarate supports glucuronidation, the complementary Phase II detoxification pathway that conjugates and excretes estrogen metabolites.

Omega-3 fatty acids support anti-inflammatory pathways that may complement DIM's effects in hormone-sensitive tissues.

Avoid Combining With

  • Oral contraceptives and hormone therapies (may theoretically alter efficacy — consult clinician)
  • Tamoxifen or aromatase inhibitors — concurrent use may interfere with therapy; discuss with oncologist
  • Heavy alcohol use (increases estrogen and may counteract metabolic goals)
Updated Invalid Date